- Home
- EWCZ vs TVRD Comparison
EWCZ vs TVRD Comparison
Compare EWCZ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- TVRD
- Stock Information
- Founded
- EWCZ 2004
- TVRD 2017
- Country
- EWCZ United States
- TVRD United States
- Employees
- EWCZ N/A
- TVRD N/A
- Industry
- EWCZ Package Goods/Cosmetics
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- TVRD Health Care
- Exchange
- EWCZ Nasdaq
- TVRD Nasdaq
- Market Cap
- EWCZ 248.8M
- TVRD 246.5M
- IPO Year
- EWCZ 2021
- TVRD N/A
- Fundamental
- Price
- EWCZ $5.43
- TVRD $26.91
- Analyst Decision
- EWCZ Buy
- TVRD Strong Buy
- Analyst Count
- EWCZ 7
- TVRD 4
- Target Price
- EWCZ $5.86
- TVRD $58.50
- AVG Volume (30 Days)
- EWCZ 566.0K
- TVRD 92.7K
- Earning Date
- EWCZ 08-13-2025
- TVRD 08-21-2025
- Dividend Yield
- EWCZ N/A
- TVRD N/A
- EPS Growth
- EWCZ N/A
- TVRD N/A
- EPS
- EWCZ 0.21
- TVRD N/A
- Revenue
- EWCZ $216,469,000.00
- TVRD N/A
- Revenue This Year
- EWCZ N/A
- TVRD N/A
- Revenue Next Year
- EWCZ $2.17
- TVRD N/A
- P/E Ratio
- EWCZ $26.09
- TVRD N/A
- Revenue Growth
- EWCZ N/A
- TVRD N/A
- 52 Week Low
- EWCZ $2.72
- TVRD $8.13
- 52 Week High
- EWCZ $10.39
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- EWCZ 47.40
- TVRD N/A
- Support Level
- EWCZ $5.44
- TVRD N/A
- Resistance Level
- EWCZ $5.84
- TVRD N/A
- Average True Range (ATR)
- EWCZ 0.24
- TVRD 0.00
- MACD
- EWCZ -0.07
- TVRD 0.00
- Stochastic Oscillator
- EWCZ 6.87
- TVRD 0.00
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.